Advertisement
Screener

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Deferred Costs, Current

2.8 / 5 stars · 68/120 Roast Me

CERO THERAPEUTICS HOLDINGS, INC. Deferred Costs, Current

CERO THERAPEUTICS HOLDINGS, INC. (CERO) had Deferred Costs, Current of $112.23 thousand as of 2024-12-31, per its 10-K filed 2026-04-15.

Financial Statements › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current

us-gaap:DeferredCostsCurrent · last filed 2026-04-15

  • 2024-12-31: Deferred Costs, Current $112.23K.
  • 2023-06-30: Deferred Costs, Current $8.75M.
Period endDeferred Costs, Current
2024-12-31$112.23K
10-K · filed 2026-04-15
2023-06-30$8.75M
10-Q · filed 2023-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
AIM ImmunoTech Inc. (AIM)United States$0.006B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
IN8BIO, INC. (INAB)United States$0.012B-0.76
CURIS INC (CRIS)United States$0.002B-0.05